Dual‐Action Psoriasis Therapy: Antiproliferative and Immunomodulatory Effects via Self‐Locking Microneedles
Abstract Psoriasis is a chronic, immune‐mediated disorder characterized by immune regulation disorders and abnormal keratinocyte proliferation. Deucravacitinib (Deu), a selective oral Tyrosine Kinase 2 (TYK2) inhibitor, shows promise in treating psoriasis but may cause systemic side effects and fail...
Saved in:
| Main Authors: | Zi Yi Wang, Ze Qiang Zhao, Yu Jun Sheng, Ke Jun Chen, Bo Zhi Chen, Xin Dong Guo, Yong Cui |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202409359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploring the effect of deucravacitinib in patients with palmoplantar pustular psoriasis
by: David A. De Luca, et al.
Published: (2024-12-01) -
Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis
by: Caroline Glatzel, et al.
Published: (2025-05-01) -
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
by: Neil J. Korman, et al.
Published: (2024-12-01) -
Successful treatment by deucravacitinib of psoriasis refractory to apremilast
by: Shigeki Inui, et al.
Published: (2025-06-01) -
Successful Psoriasis Management With Deucravacitinib After Guselkumab‐Associated Eosinophilic Pneumonia
by: Katie K. Lovell, et al.
Published: (2025-06-01)